JP2025504017A - Ｂ型肝炎ウイルス感染症を処置するための組合せ療法 - Google Patents

Ｂ型肝炎ウイルス感染症を処置するための組合せ療法 Download PDF

Info

Publication number
JP2025504017A
JP2025504017A JP2024544889A JP2024544889A JP2025504017A JP 2025504017 A JP2025504017 A JP 2025504017A JP 2024544889 A JP2024544889 A JP 2024544889A JP 2024544889 A JP2024544889 A JP 2024544889A JP 2025504017 A JP2025504017 A JP 2025504017A
Authority
JP
Japan
Prior art keywords
compound
wing segment
modified oligonucleotide
weeks
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504017A5 (https=
Inventor
ジャレッド、ローレン、デラヘイ
マーティン、アール、レイバース
マレク、オコア
シヒョン、キーファー、ユ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2025504017A publication Critical patent/JP2025504017A/ja
Publication of JP2025504017A5 publication Critical patent/JP2025504017A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024544889A 2022-01-28 2023-01-26 Ｂ型肝炎ウイルス感染症を処置するための組合せ療法 Pending JP2025504017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263304091P 2022-01-28 2022-01-28
US63/304,091 2022-01-28
PCT/IB2023/050687 WO2023144750A1 (en) 2022-01-28 2023-01-26 Combination therapy for treating hepatitis b virus infections

Publications (2)

Publication Number Publication Date
JP2025504017A true JP2025504017A (ja) 2025-02-06
JP2025504017A5 JP2025504017A5 (https=) 2026-02-03

Family

ID=85172882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544889A Pending JP2025504017A (ja) 2022-01-28 2023-01-26 Ｂ型肝炎ウイルス感染症を処置するための組合せ療法

Country Status (8)

Country Link
US (1) US20250092401A1 (https=)
EP (1) EP4469161A1 (https=)
JP (1) JP2025504017A (https=)
KR (1) KR20240144245A (https=)
CN (1) CN118660704A (https=)
AU (1) AU2023213173B2 (https=)
CA (1) CA3243401A1 (https=)
WO (1) WO2023144750A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202340468A (zh) 2022-01-10 2023-10-16 中國大陸商杭州浩博醫藥有限公司 B型肝炎病毒(hbv)表現之調節
CN118667808B (zh) * 2023-08-22 2025-04-18 浙江柏拉阿图医药科技有限公司 双‐Gap修饰寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61447B1 (sr) 2011-04-21 2021-03-31 Glaxo Group Ltd Modulacija ekspresije virusa hepatitisa b (hbv)
EP4219767A1 (en) * 2016-06-17 2023-08-02 F. Hoffmann-La Roche AG Papd5 and papd7 inhibitors for treating a hepatitis b infection
KR20190057277A (ko) * 2016-06-24 2019-05-28 에모리 유니버시티 B형 간염 바이러스 치료용 포스포아미데이트
FI3692040T3 (fi) * 2017-10-05 2023-03-29 Glaxosmithkline Ip Dev Ltd Kemiallisia yhdisteitä

Also Published As

Publication number Publication date
AU2023213173B2 (en) 2026-04-23
CN118660704A (zh) 2024-09-17
EP4469161A1 (en) 2024-12-04
US20250092401A1 (en) 2025-03-20
KR20240144245A (ko) 2024-10-02
CA3243401A1 (en) 2023-08-03
WO2023144750A1 (en) 2023-08-03
AU2023213173A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
Gane et al. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials
Liang et al. Present and future therapies of hepatitis B: from discovery to cure
Cheng et al. Clinical effects of NTCP‐inhibitor myrcludex B
Mueller et al. A novel orally available small molecule that inhibits hepatitis B virus expression
Dusheiko Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues
Wranke et al. Antiviral therapy of hepatitis delta virus infection—progress and challenges towards cure
DK2694087T3 (en) The treatment of infection with Hepatitis B virus alone or in combination with hepatitis delta virus, and in connection with liver diseases
JP2025504017A (ja) Ｂ型肝炎ウイルス感染症を処置するための組合せ療法
TW202221122A (zh) Ｂ型肝炎患者之寡核苷酸治療
Stein et al. Drug targets in hepatitis B virus infection
JP2025511096A (ja) 慢性ｂ型肝炎を治療する方法
Danta et al. Adefovir dipivoxil: review of a novel acyclic nucleoside analogue
Khan et al. Developments in pharmacotherapeutic agents for hepatitis B–how close are we to a functional cure?
EP2519243B1 (en) Compositions and methods for treating hepatitis b virus infection
Lucifora et al. The life cycle of hepatitis B virus and antiviral targets
Offensperger et al. Therapy of hepadnavirus infection using antisense oligonucleotides
Marchetti Proteomic Analysis of Nuclear HBV rcDNA Associated Proteins Identifies UV-DDB as a Host Factor Involved in cccDNA Formation
CN115337310A (zh) 一种抗炎剂在制备治疗或预防病毒性肝炎药物的应用
Hodge Meeting report: 27th International conference on antiviral research, in Raleigh, NC, USA
CN114224888B (zh) 兰索拉唑在制备治疗或预防病毒性肝炎用药物中的用途
Woodson Biological and Pharmacological Characterization of Novel HBV Ribonuclease H Inhibitors
Guo et al. New Insights on Molecular Mechanism of Hepatitis B Virus Covalently Closed Circular DNA Formation
WO2025262623A1 (en) Method of treating hbv/hiv coinfection
CN118973587A (zh) 治疗慢性乙型肝炎的方法
Mak et al. Hepatitis B: treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260126